Crinetics Announces October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces October 2022 inducement grants: the stock options were granted as inducements material to 11 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism


The UK Medicines and Healthcare products Regulatory Agency has granted CRN04777 an “Innovation Passport” for the treatment of congenital hyperinsulinism.

Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer


Crinetics appoints Dana Pizzuti, M.D., a 30-year pharmaceutical industry veteran, to the newly created role of chief development officer

Crinetics Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces September 2022 inducement grants: the stock options were granted as inducements material to 13 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference


Crinetics Pharmaceuticals management will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022